JP2021121645A - 15β−ヒドロキシ−酢酸オサテロンの結晶多形 - Google Patents
15β−ヒドロキシ−酢酸オサテロンの結晶多形 Download PDFInfo
- Publication number
- JP2021121645A JP2021121645A JP2021094176A JP2021094176A JP2021121645A JP 2021121645 A JP2021121645 A JP 2021121645A JP 2021094176 A JP2021094176 A JP 2021094176A JP 2021094176 A JP2021094176 A JP 2021094176A JP 2021121645 A JP2021121645 A JP 2021121645A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- polymorph
- osaterone acetate
- diffraction
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PUVIUQNYQQPAQB-LZGXPLDUSA-N [(1r,3r,3as,3br,9ar,9bs,11as)-1-acetyl-5-chloro-3-hydroxy-9a,11a-dimethyl-7-oxo-2,3,3a,3b,9,9b,10,11-octahydroindeno[4,5-h]isochromen-1-yl] acetate Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 PUVIUQNYQQPAQB-LZGXPLDUSA-N 0.000 title claims abstract description 51
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 14
- 238000001228 spectrum Methods 0.000 claims abstract description 11
- 238000002844 melting Methods 0.000 claims abstract description 8
- 230000008018 melting Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000012046 mixed solvent Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000013078 crystal Substances 0.000 abstract description 59
- 238000003860 storage Methods 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 238000010583 slow cooling Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- -1 alkanes) Chemical class 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KKTIOMQDFOYCEN-OFUYBIASSA-N Osaterone acetate Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 KKTIOMQDFOYCEN-OFUYBIASSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
回折角度2θ=12.1°での回折強度A2=52〜72(例えば、55〜70)、好ましくは57〜67(例えば、60〜65)
回折角度2θ=14.6°での回折強度A3=8〜28(例えば、10〜25)、好ましくは13〜23(例えば、15〜20)
回折角度2θ=15.0°での回折強度A4=39〜59(例えば、42〜56)、好ましくは44〜54(例えば、46〜51)
回折角度2θ=16.2°での回折強度A5=9〜29(例えば、12〜26)、好ましくは14〜24(例えば、16〜21)
回折角度2θ=20.2°での回折強度A6=40〜60(例えば、43〜57)、好ましくは45〜55(例えば、47〜52)
回折角度2θ=20.9°での回折強度A7=13〜33(例えば、15〜30)、好ましくは18〜28(例えば、20〜25)
回折角度2θ=24.9°での回折強度A8=6〜26(例えば、8〜23)、好ましくは11〜21(例えば、13〜18)
回折角度2θ=25.6°での回折強度A9=6〜26(例えば、8〜23)、好ましくは11〜21(例えば、13〜18)
15β−ヒドロキシ−酢酸オサテロンの結晶多形Aは、種々の結晶化方法で得ることができ、例えば、15β−ヒドロキシ−酢酸オサテロンを有機溶媒(クロロホルムなどの良溶媒)に溶解し、この溶液を貧溶媒(オクタンなどの貧溶媒)と混合して晶析することにより得てもよい。このような析出法では、他の結晶多形を含む結晶多形Aが得られる場合がある。そのため、代表的には、過飽和状態の溶液から晶析する方法、例えば、有機溶媒を含む晶析溶媒(例えば、良溶媒と貧溶媒との混合溶媒)に溶解して飽和状態の溶液を調製し、この溶液を冷却(特に、徐冷)することにより、結晶多形Aを析出させることができる。
本発明の15β−ヒドロキシ−酢酸オサテロンの結晶多形Aは、単独で医薬として用いてもよく、担体(薬理学的又は生理学的に許容可能な担体など)と組み合わせて医薬組成物(又は製剤)として用いてもよい。
特許文献1の実施例3(f)と同様にして15β−ヒドロキシ−酢酸オサテロン(17α−アセトキシ−6−クロロ−15β−ヒドロキシ−2−オキサプレグナ−4,6−ジエン−3,20−ジオン)を調製した。得られた15β−ヒドロキシ−酢酸オサテロン1gにエタノール/水(25:1)混合溶媒20mLを加え、混合液を還流して15β−ヒドロキシ−酢酸オサテロンを溶解した後、室温で1晩徐冷した。析出した結晶をろ過し、少量の前記混合溶媒で洗浄した。室温で通風乾燥して結晶多形A0.65gを得た。
非特許文献1に記載の方法に基づき、15β−ヒドロキシ−酢酸オサテロン(結晶多形B)を得た。
実施例1で得られた結晶多形Aと比較例1で得られた結晶多形Bとを、それぞれ、温度100℃で28日間保存(保存条件、恒温槽 空気中)し、所定時間毎にサンプリングしてHPLCで15β−ヒドロキシ−酢酸オサテロンの純度を測定した。結果を図5に示す。
自動乳鉢粉砕器(乳棒重量124g、50回転/分)に試料(結晶多形A又は結晶多形B)50mgを入れ、1時間に亘り粉砕し、サンプリングした。PXRD分析を行い、結晶化度の変化を確認したところ、1時間後の結晶化度は、結晶多形A46.8%、結晶多形B22.2%であり、結晶多形Aが粉砕に対して安定であった。なお、PXRDスペクトルでの特徴的な回析ピーク(結晶多形Aでは2θ=17.1°での回析ピーク、結晶多形Bでは2θ=16.2°での回析ピーク)の強度比(ピーク高さ)に基づいて結晶化度を測定し、結晶化度の変化率を算出した。
ロート下端から堆積面(直径1.5cmの円柱の上面)までの高さを4.5cmに固定し、ロートを通して円柱面の中心部に過剰の粉末を落下させた。堆積した粉体の傾斜角(安息角)を測定した。この操作を3回繰り返し、安息角の平均値を算出した。
(1)アセトン/ヘプタン混合溶媒(1:1)、(2)アセトン/水混合溶媒(1:1)、(3)エタノール/水混合溶媒(1:1)に結晶多形Aを加えて撹拌したところ、結晶多形Aは、1日後、混合溶媒(1)では98%、混合溶媒(2)では99%、混合溶媒(3)では100%の割合で結晶多形Aの結晶構造を保持し、3日後、混合溶媒(1)では95%、混合溶媒(2)では98%、混合溶媒(3)では99%の割合で結晶多形Aの結晶構造を保持し、7日後でも混合溶媒(1)では95%、混合溶媒(2)では98%、混合溶媒(3)では99%の割合で結晶多形Aの結晶構造を保持していた。
実施例1で得られた結晶多形Aおよび比較例1で得られた結晶多形Bを、0.3mg/kgの用量で乳糖水和物(DFE Pharma社製)100mgと混合し、ゼラチンカプセル((株)松屋製MM、サイズ:2号)に充填してカプセル剤を調製した。第1群(5頭)の雌性イヌに結晶多形Aを含むカプセル剤を経口投与し、第2群(5頭)の雌性イヌに結晶多形Bを含むカプセル剤を経口投与し、それぞれ、経口投与後0.5、1、2、3、4、5、7、10、24、48及び72時間に血液を採取し、遠心分離により血漿を得た。LC−MS/MS(液体クロマトグラフィー−タンデム質量分析)法により、血漿中の15β−ヒドロキシ−酢酸オサテロン濃度を測定し、最高血漿中濃度到達時間(Tmax)および最高血漿濃度(Cmax)を算出した。
Claims (4)
- 15β−ヒドロキシ−酢酸オサテロンの結晶多形であって、粉末X線回折スペクトルにおいて、以下の回折角度2θに回折ピークを有する15β−ヒドロキシ−酢酸オサテロンの結晶多形A。
9.6°±0.2°,17.1°±0.2°,20.2°±0.2°,25.6°±0.2° - 融点280〜283℃を有する請求項1記載の15β−ヒドロキシ−酢酸オサテロンの結晶多形A。
- 15β−ヒドロキシ−酢酸オサテロンをエタノールと水との混合溶媒に加熱して溶解し、溶液を冷却し、請求項1又は2記載の15β−ヒドロキシ−酢酸オサテロンの結晶多形Aを製造する方法。
- 請求項1又は2記載の15β−ヒドロキシ−酢酸オサテロンの結晶多形Aと担体とを含む経口投与製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016095382 | 2016-05-11 | ||
JP2016095382 | 2016-05-11 | ||
JP2018517047A JP7210278B2 (ja) | 2016-05-11 | 2017-05-10 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517047A Division JP7210278B2 (ja) | 2016-05-11 | 2017-05-10 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021121645A true JP2021121645A (ja) | 2021-08-26 |
JP7241807B2 JP7241807B2 (ja) | 2023-03-17 |
Family
ID=60267316
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517047A Active JP7210278B2 (ja) | 2016-05-11 | 2017-05-10 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
JP2021094176A Active JP7241807B2 (ja) | 2016-05-11 | 2021-06-04 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517047A Active JP7210278B2 (ja) | 2016-05-11 | 2017-05-10 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10508130B2 (ja) |
EP (1) | EP3456729B1 (ja) |
JP (2) | JP7210278B2 (ja) |
KR (1) | KR102383617B1 (ja) |
CN (1) | CN109153701B (ja) |
AU (1) | AU2017264187B2 (ja) |
BR (1) | BR112018071950A2 (ja) |
CA (1) | CA3021179A1 (ja) |
EA (1) | EA034965B1 (ja) |
ES (1) | ES2829578T3 (ja) |
MX (1) | MX2018013786A (ja) |
MY (1) | MY195203A (ja) |
PH (1) | PH12018502365A1 (ja) |
SG (1) | SG11201809127PA (ja) |
WO (1) | WO2017195804A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018071950A2 (pt) * | 2016-05-11 | 2019-02-05 | Aska Pharm Co Ltd | forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, processo para a produção de uma forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, e composição farmacêutica |
MX2022003983A (es) * | 2019-10-02 | 2022-04-26 | Aska Pharm Co Ltd | Agente mejorador de los trastornos de la miccion. |
US20240041899A1 (en) * | 2020-12-18 | 2024-02-08 | Aska Pharmaceutical Co., Ltd. | Solid preparation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2591640B2 (ja) * | 1988-02-04 | 1997-03-19 | 帝国臓器製薬株式会社 | 新規な2−オキサプレグナン化合物 |
WO2017195804A1 (ja) * | 2016-05-11 | 2017-11-16 | あすか製薬株式会社 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61204199A (ja) * | 1985-03-07 | 1986-09-10 | Teikoku Hormone Mfg Co Ltd | 2−アザプレグナン化合物 |
US4785103A (en) | 1985-03-07 | 1988-11-15 | Teikoku Hormone Mfg. Co., Ltd. | 2-oxa- or -aza-pregnane compounds |
JPS61204198A (ja) * | 1985-03-07 | 1986-09-10 | Teikoku Hormone Mfg Co Ltd | 2−オキサプレグナン化合物 |
JPS62195398A (ja) * | 1986-02-21 | 1987-08-28 | Teikoku Hormone Mfg Co Ltd | 黄体ホルモン剤 |
JP2980992B2 (ja) * | 1990-12-28 | 1999-11-22 | 帝国臓器製薬株式会社 | 6−ハロゲノ−2−オキサプレグナ−4,6−ジエン−3−オン化合物の製造方法 |
JP2591640Y2 (ja) | 1993-05-13 | 1999-03-10 | 株式会社吉野工業所 | 液体収納袋 |
US7742606B2 (en) | 2004-03-26 | 2010-06-22 | Harman International Industries, Incorporated | System for audio related equipment management |
JP6192228B2 (ja) | 2014-05-23 | 2017-09-06 | 本田技研工業株式会社 | 物体認識装置 |
-
2017
- 2017-05-10 BR BR112018071950A patent/BR112018071950A2/pt active Search and Examination
- 2017-05-10 WO PCT/JP2017/017619 patent/WO2017195804A1/ja unknown
- 2017-05-10 AU AU2017264187A patent/AU2017264187B2/en active Active
- 2017-05-10 MX MX2018013786A patent/MX2018013786A/es active IP Right Grant
- 2017-05-10 ES ES17796164T patent/ES2829578T3/es active Active
- 2017-05-10 JP JP2018517047A patent/JP7210278B2/ja active Active
- 2017-05-10 US US16/095,782 patent/US10508130B2/en active Active
- 2017-05-10 KR KR1020187035313A patent/KR102383617B1/ko active IP Right Grant
- 2017-05-10 CA CA3021179A patent/CA3021179A1/en active Pending
- 2017-05-10 SG SG11201809127PA patent/SG11201809127PA/en unknown
- 2017-05-10 EA EA201892566A patent/EA034965B1/ru not_active IP Right Cessation
- 2017-05-10 MY MYPI2018001883A patent/MY195203A/en unknown
- 2017-05-10 CN CN201780028401.XA patent/CN109153701B/zh active Active
- 2017-05-10 EP EP17796164.6A patent/EP3456729B1/en active Active
-
2018
- 2018-11-09 PH PH12018502365A patent/PH12018502365A1/en unknown
-
2021
- 2021-06-04 JP JP2021094176A patent/JP7241807B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2591640B2 (ja) * | 1988-02-04 | 1997-03-19 | 帝国臓器製薬株式会社 | 新規な2−オキサプレグナン化合物 |
WO2017195804A1 (ja) * | 2016-05-11 | 2017-11-16 | あすか製薬株式会社 | 15β-ヒドロキシ-酢酸オサテロンの結晶多形 |
Non-Patent Citations (3)
Title |
---|
CHEM. PHARM. BULL., vol. 1993, Vol.41, No.5, JPN7020002917, pages 870 - 875, ISSN: 0004965861 * |
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 1979, Vol.68, No.2, JPN7020002918, pages 175 - 177, ISSN: 0004965863 * |
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 2009, Vol.13, No.6, JPN6020035450, pages 1241 - 1253, ISSN: 0004965862 * |
Also Published As
Publication number | Publication date |
---|---|
CN109153701A (zh) | 2019-01-04 |
EA201892566A1 (ru) | 2019-04-30 |
CA3021179A1 (en) | 2017-11-16 |
US10508130B2 (en) | 2019-12-17 |
AU2017264187A1 (en) | 2018-11-15 |
JP7210278B2 (ja) | 2023-01-23 |
WO2017195804A1 (ja) | 2017-11-16 |
EP3456729A4 (en) | 2019-05-22 |
ES2829578T3 (es) | 2021-06-01 |
KR20190004787A (ko) | 2019-01-14 |
BR112018071950A2 (pt) | 2019-02-05 |
CN109153701B (zh) | 2021-02-02 |
KR102383617B1 (ko) | 2022-04-05 |
US20190127417A1 (en) | 2019-05-02 |
EP3456729A1 (en) | 2019-03-20 |
MY195203A (en) | 2023-01-11 |
AU2017264187B2 (en) | 2021-02-18 |
MX2018013786A (es) | 2019-03-28 |
PH12018502365A1 (en) | 2019-09-09 |
SG11201809127PA (en) | 2018-11-29 |
JP7241807B2 (ja) | 2023-03-17 |
EA034965B1 (ru) | 2020-04-13 |
JPWO2017195804A1 (ja) | 2019-03-07 |
EP3456729B1 (en) | 2020-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4334869B2 (ja) | 溶解性または経口吸収性の改善された組成物 | |
JP2021121645A (ja) | 15β−ヒドロキシ−酢酸オサテロンの結晶多形 | |
BR112017018533B1 (pt) | Composição que compreende uma dispersão sólida de ospemifeno e seu método de preparação | |
EA027641B1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
JP5809367B2 (ja) | レボノルゲストレルの結晶多形α及びその製造方法 | |
JP5809368B2 (ja) | レボノルゲストレルの結晶多形β及びその製造方法 | |
JP6200493B2 (ja) | 無定形ウリプリスタール酢酸エステル | |
JP2015532263A (ja) | ウリプリスタール酢酸エステルの結晶多形 | |
EP2900683B1 (en) | Crystalline polymorphic form of ulipristal acetate | |
JP2004210702A (ja) | 5−[(1z,2e)−2−メチル−3−フェニル−2−プロペニリデン]−4−オキソ−2−チオキソ−3−チアゾリジン酢酸の新規結晶、その製造方法およびその結晶を有効成分とする医薬 | |
JP6433910B2 (ja) | レボノルゲストレルの新規結晶混合物及びその製造方法 | |
KR20200136399A (ko) | 브렉스피프라졸을 포함하는 약학 조성물 | |
WO2007069675A1 (ja) | キサンチン誘導体の易吸収性経口製剤 | |
TW201522361A (zh) | 非晶形烏普司他醋酸 | |
TW201522360A (zh) | 烏普司他醋酸之結晶多晶型 | |
TW201522362A (zh) | 烏普司他醋酸之結晶多晶型 | |
JP2004210766A (ja) | 5−[(1z,2e)−2−メチル−3−フェニル−2−プロペニリデン]−4−オキソ−2−チオキソ−3−チアゾリジン酢酸の新規結晶の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230307 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7241807 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |